AbbVie Partners With Alloy Therapeutics To Build Next-Gen Antibody Discovery Platform

Alloy Therapeutics has entered into a multi-year agreement with AbbVie to develop a new antibody discovery platform aimed at addressing challenging targets. Alloy will receive an upfront payment and additional compensation upon delivery of the platform. The collaboration enhances AbbVie's research capabilities and aligns with Alloy's mission to advance antibody therapeutics through innovative platform technologies. Alloy's ATX-Gx platform is already utilized by over 200 partners in therapeutic discovery.